The investigation of DNA repair polymorphisms with histopathological characteristics and hormone receptors in a group of Brazilian women with breast cancer

Genetics and Molecular Research

Volumn 7, Issue 3, 2008, Pages 574-582

  Dufloth, R M ^a   Arruda, A ^b   Heinrich, J K R ^b   Schmitt, F ^c   Zeferino, L C ^b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c University of Porto   (Portugal)

Author keywords

Breast cancer; Estrogen; Hereditary disease; Polymorphisms

Indexed keywords

ARGININE; ESTROGEN RECEPTOR; GLUTAMINE; LYSINE; RAD51 PROTEIN; THREONINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; XRCC3 PROTEIN;

ARTICLE; BLOOD SAMPLING; BREAST CARCINOMA; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; DNA REPAIR; FEMALE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; MORPHOLOGICAL TRAIT; MUCINOUS CARCINOMA; PAPILLARY CARCINOMA;

EID: 49749134331     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/vol7-3gmr376     Document Type: Article

References (28)

1. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, et al. (2004). Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol. Biomarkers Prev. 13: 1558-1568.
2. Brewster AM, Jorgensen TJ, Ruczinski I, Huang HY, et al. (2006). Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer. Breast Cancer Res. Treat. 95: 73-80.
3. Clarkson SG and Wood RD (2005). Polymorphisms in the human XPD (ERCC2) gene, DNA repair capacity and cancer susceptibility: an appraisal. DNA Repair 4: 1068-1074.
4. Costa S, Pinto D, Pereira D, Rodrigues h, et al. (2007). DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res. Treat. 103: 209-217.
5. Costa S, Pinto D, Pereira D, Rodrigues h, et al. (2008). XRCC1 Arg399Gln and RAD51 5′UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients. Breast Cancer Res. Treat. 109: 183-185.
6. de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, et al. (2002). Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J. Med. Genet. 39: 225-242.
7. Dowsett M and Ashworth A (2003). New biology of the oestrogen receptor. Lancet 362: 260-262.
8. Dufloth RM, Costa S, Schmitt F and Zeferino LC (2005). DNA repair gene polymorphisms and susceptibility to familial breast cancer in a group of patients from Campinas, Brazil. Genet. Mol. Res. 4: 771-782.
9. Elston CW, Ellis IO and Pinder SE (1999). Pathological prognostic factors in breast cancer. Crit. Rev. Oncol. Hematol. 31: 209-223.
10. Enger SM, Ross RK, Paganini-hill A, Carpenter CL, et al. (2000). Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol. Biomarkers Prev. 9: 681-687.
11. Foulks WD, Metacalfe K, Sun P, hanna WM, et al. (2004). Estrogen receptor status in BRCA1- and BRCA2-related breast cancer. Clin. Cancer Res. 10: 2029-2034.
12. Gruvberger S, Ringner M, Chen Y, Panavally S, et al. (2001). Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61: 5979-5984.
13. Johnson-Thompson MC and Guthrie J (2000). Ongoing research to identify environmental risk factors in breast carcinoma. Cancer 88: 1224-1229.
14. Lakhani SR (1999). The pathology of familial breast cancer: morphological aspects. Breast Cancer Res. 1: 31-35.
15. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, et al. (1998). Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 90: 1138-1145.
16. Lakhani SR, Van Den Vijver MJ, Jacquemier J, Anderson TJ, et al. (2002). The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, hER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 20: 2310-2318.
17. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, et al. (2005). Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res. 11: 5175-5180.
18. Ma H, Bernstein L, Pike MC and Ursin G (2006). Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 8: R43.
19. Matos I, Dufloth R, Alvarenga M, Zeferino LC, et al. (2005). p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 447: 688-694.
20. McCredie MR, Dite GS, Southey MC, Venter DJ, et al. (2003). Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status. Br. J. Cancer 89: 1661-1663.
21. Metsola K, Kataja V, Sillanpaa P, Siivola P, et al. (2005). XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study. Breast Cancer Res. 7: R987-R997.
22. Murphy L, Cherlet T, Lewis A, Banu Y, et al. (2003). New insights into estrogen receptor function in human breast cancer. Ann. Med. 35: 614-631.
23. Noruzinia M, Coupier I and Pujol P (2005). Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent? Cancer 104: 1567-1574.
24. Rebbeck TR (1999). Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer 86: 2493-2501.
25. Reis-Filho JS and Tutt AN (2008). Triple negative tumours: a critical review. Histopathology 52: 108-118.
26. Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, et al. (2001). The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim. Biophys. Acta 1471: C1-C10.
27. Smith TR, Levine EA, Perrier ND, Miller MS, et al. (2003). DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 12: 1200-1204.
28. Tavassoli FK and Devilee P (2003). World Health Organization Classification of Tumours: Pathology and Genetic of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon.